Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

NCT02576977 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

251

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early due to business reasons

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Pomalidomide
DRUG: Dexamethasone

Sponsor

Merck Sharp & Dohme LLC